Candriam Luxembourg S.C.A. raised its position in Intra-Cellular Therapies Inc. (NASDAQ:ITCI) by 14.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 177,000 shares of the biopharmaceutical company’s stock after purchasing an additional 22,000 shares during the quarter. Candriam Luxembourg S.C.A. owned 0.33% of Intra-Cellular Therapies worth $2,793,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Goldman Sachs Group Inc. raised its position in Intra-Cellular Therapies by 336.1% in the 2nd quarter. Goldman Sachs Group Inc. now owns 580,770 shares of the biopharmaceutical company’s stock worth $7,213,000 after purchasing an additional 447,586 shares during the period. First Midwest Bank Trust Division raised its position in Intra-Cellular Therapies by 18.2% in the 3rd quarter. First Midwest Bank Trust Division now owns 184,836 shares of the biopharmaceutical company’s stock worth $2,917,000 after purchasing an additional 28,487 shares during the period. Federated Investors Inc. PA raised its position in Intra-Cellular Therapies by 113.3% in the 2nd quarter. Federated Investors Inc. PA now owns 183,035 shares of the biopharmaceutical company’s stock worth $2,273,000 after purchasing an additional 97,228 shares during the period. Fox Run Management L.L.C. purchased a new stake in Intra-Cellular Therapies in the 3rd quarter worth about $390,000. Finally, Dimensional Fund Advisors LP raised its position in Intra-Cellular Therapies by 192.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 124,622 shares of the biopharmaceutical company’s stock worth $2,025,000 after purchasing an additional 81,969 shares during the period. 59.55% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Candriam Luxembourg S.C.A. Has $2.79 Million Position in Intra-Cellular Therapies Inc. (ITCI)” was first reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.themarketsdaily.com/2017/11/16/candriam-luxembourg-s-c-a-has-2-79-million-position-in-intra-cellular-therapies-inc-itci.html.
Intra-Cellular Therapies (NASDAQ:ITCI) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.53) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.53). The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.06 million. Intra-Cellular Therapies had a negative net margin of 28,038.35% and a negative return on equity of 27.40%. The company’s quarterly revenue was up 675.0% compared to the same quarter last year. During the same period last year, the company posted ($0.70) earnings per share. research analysts predict that Intra-Cellular Therapies Inc. will post -2.16 earnings per share for the current year.
In other Intra-Cellular Therapies news, major shareholder Alafi Capital Co Llc acquired 258,065 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The shares were bought at an average cost of $15.50 per share, with a total value of $4,000,007.50. Following the completion of the acquisition, the insider now directly owns 3,953,270 shares in the company, valued at approximately $61,275,685. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Sharon Mates sold 18,750 shares of Intra-Cellular Therapies stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $15.75, for a total transaction of $295,312.50. Following the transaction, the chief executive officer now directly owns 1,107,457 shares in the company, valued at $17,442,447.75. The disclosure for this sale can be found here. Company insiders own 19.80% of the company’s stock.
A number of research firms recently weighed in on ITCI. Piper Jaffray Companies raised shares of Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $14.00 to $33.00 in a research report on Thursday, September 7th. JMP Securities raised shares of Intra-Cellular Therapies from a “market perform” rating to an “outperform” rating and set a $24.00 price objective on the stock in a research report on Thursday, August 24th. ValuEngine raised shares of Intra-Cellular Therapies from a “strong sell” rating to a “sell” rating in a research report on Friday, August 18th. Cowen and Company reissued an “outperform” rating and issued a $27.00 price objective (up from $20.00) on shares of Intra-Cellular Therapies in a research report on Friday, September 8th. Finally, SunTrust Banks, Inc. raised shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a research report on Wednesday, November 8th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. Intra-Cellular Therapies has a consensus rating of “Buy” and an average target price of $25.00.
Intra-Cellular Therapies Profile
Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).
Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.